L'Agence nationale de la recherche Des projets pour la science

Investissements d'avenirProjets financés


Innovations instrumentales et procédurales en psychopathologie expérimentale chez le rongeur (OPTOPATH)


Action : Equipements d'excellence


N° de convention : 10-EQPX-0008

Informations générales

  • Référence projet : 10-EQPX-0008
  • RST : Véronique DEROCHE-GAMONET
  • Etablissement Coordinateur : Université de Bordeaux
  • Région du projet : Nouvelle Aquitaine
  • Discipline : 5 - Bio Med
  • Aide allouée : 5 998 560 €
  • Date de début du projet : 22/02/2011
  • Date de fin du projet : 31/12/2019
  • Site web du projet : http://optopath.equipex.u-bordeaux.fr/en/OptoPath/r608.html
  • Mots clés : Health, Addiction, Obesity, Memory deficits, Stress/Anxiety Disorders, PTSD, Experimental psychology, Neurophysiology, In vivo Electrophysiology, Optogenetic, In vivo microscopy.

Résumé du projet

Obesity, drug addiction, aging-related memory deficits and post-traumatic stress disorders are expanding pathologies. To master their expansion and offer better treatments, it is critical to improve knowledge on their underlying pathophysiological mechanisms. Hence, animal models are key tools. However, research is facing two difficulties: the lack of reliable behavioral models of these psychopathologies and the lack of technologies for studying the underlying brain functional alterations in real time. Eight research teams, from two renowned neuroscience centers, supported by two private partners, have joint forces to create a research platform to address these challenges. This project relies on two pillars: sharing of means (financial, human and technological) and federation of expertise. Phase 1, granted 5.5 M€ by the IA-EquipEx program, ran from 1/09/2011 to 30/06/2016 and has consisted in conceptualizing, testing, validating new behavioral equipment and procedures for coupling with innovative neurobiological research tools. It also involved de novo building of 450 m2 of dedicated laboratory facilities funded by Inserm (1.8 M€). OptoPath has been fully operational since it entered in phase 2 on 01/07/2016. Granted 500 K€ by the IA-EquipEx, phase 2 is dedicated to creating value from this equipment through: 1) acquisition of knowledge on the neurobiology of the pathologies of interest, 2) services offer and, 3) equipment sale. OptoPath offers to its 8 research teams a unique space to: 1) develop internal collaborations in a transnosographic perspective, 2) attract new external collaborations, 3) externalize technological development from their own lab, 4) value their expertise through training offers and research contracts to pharmaceutical industries or academics. Because some equipment were operational before the end of phase 1, they have already created value through publications in high impact journals, cutting edge training offers and research contracts.

(L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.)